In vivo induction of necrosis in mice fibrosarcoma via intravenous injection of type B staphylococcal enterotoxin
In vivo induction of necrosis in mice fibrosarcoma via intravenous injection of type B staphylococcal enterotoxin
复制标题
DOI：
10.1007/s10529-008-9805-3
复制
发表时间：
2008-12-01
影响因子：
2.7
通讯作者：
Horii, Akira
中科院分区：
文献类型：
--
作者：
Fooladi, Abbas Ali Imani;Sattari, Morteza;Horii, Akira
细菌超抗原葡萄球菌肠毒素 B (SEB) 是体内细胞毒性 T 细胞活性和细胞因子产生的有效诱导剂。我们研究了 SEB 在纤维肉瘤患者中的治疗应用的可能性。通过静脉内 (IV) 和瘤内 (IT) 注射检查 SEB 对接种纤维肉瘤 (WEHI-164) 小鼠的抗肿瘤作用，并测定接种肿瘤的大小、IFN-γ 产生和 CD4+/CD8+ T 细胞浸润。还对接种的肿瘤进行组织学检查。与 IT 注射组和对照组的小鼠相比，IV 注射组的小鼠肿瘤大小显着减小 (P < 0.02)。此外，与其他组相比，静脉注射组小鼠的 IFN-γ 水平（P < 0.009）和 CD4+/CD8+ T 细胞浸润水平显着升高（P < 0.02）。静脉注射组小鼠肿瘤组织坏死的频率也明显较高（P < 0.05）。我们目前的研究结果表明，肿瘤细胞死亡是由静脉注射 SEB 引起的细胞毒性 T 细胞活性和细胞因子水平增加引起的，SEB 可能是纤维肉瘤患者的一种新疗法的良好选择。
The bacterial superantigen staphylococcal enterotoxin B (SEB) is a potent inducer of cytotoxic T-cell activity and cytokine production in vivo. We investigated the possibility of the therapeutic application of SEB in patients with fibrosarcoma. The anti-tumor effect of SEB in mice with inoculated fibrosarcoma (WEHI-164) was examined by intravenous (IV) and intratumoral (IT) injection and the sizes of the inoculated tumors, IFN-gamma production, and CD4+/CD8+ T cell infiltration were determined. The inoculated tumors were also examined histologically. In the mice in the IV-injected group, a significant reduction (P < 0.02) of tumor size was observed in comparison with mice in the IT-injected and control groups. Furthermore, the mice in the IV-injected group showed significantly higher levels of IFN-gamma (P < 0.009) and CD4+/CD8+ T cell infiltration when compared with the other groups (P < 0.02). A significantly higher frequency of necrosis in tumor tissues was also observed in mice in the IV-injected group (P < 0.05). Our present findings suggest that tumor cell death is caused by increased cytotoxic T-cell activity and cytokine levels in response to the IV injection of SEB and that SEB may be a good option for use as a novel therapy in patients with fibrosarcoma.